AOD-9604
aod9604
research_page
AOD-9604 Peptide Research
AOD-9604 Peptide Research
Reviewing the evidence behind the hGH fragment AOD-9604
AOD-9604 is a synthetic fragment of human growth hormone developed to explore lipolytic and anti-obesity effects without the full endocrine profile of native growth hormone.
AOD-9604 is a synthetic fragment of human growth hormone developed to explore lipolytic and anti-obesity effects without the full endocrine profile of native growth hormone.
Some of the biggest claims about AOD-9604 move faster than the evidence. This page focuses on what the published research actually shows.
AOD-9604 is a synthetic fragment of human growth hormone developed to explore lipolytic and anti-obesity effects without the full endocrine profile of native growth hormone. It remains investigational, and its online reputation often exceeds the strength of the published clinical evidence.
It is derived from the C-terminal region of hGH and is proposed to influence lipolysis and inhibit lipogenesis, with less impact on IGF-1 signaling than full-length growth hormone. That theoretical separation from classic GH effects is central to its appeal in body-composition medicine.
Clinical interest focuses on obesity, body-fat reduction, and metabolic optimization, especially for people seeking a non-incretin approach or an adjunct to broader metabolic programs.
Published human trials suggest AOD-9604 was generally tolerated and produced modest fat-loss signals in some settings, but development never reached the practice-changing level seen with semaglutide or tirzepatide. Reviews comparing GH fragments and obesity pharmacology reinforce that the efficacy signal appears modest rather than transformative.
Human safety appears better characterized than many gray-market peptides, but long-term effectiveness remains uncertain and manufacturing quality is a separate issue outside formal pharmaceutical development. It should not be presented as an established obesity standard.
AOD-9604 has more human history than many experimental peptides, but the benefit signal appears modest. It fits educational content on body-composition science more than first-line obesity claims.
Low
Early Clinical
Not Approved
metabolic peptide
fat-loss|body-composition|hgh-fragment
informational
fat-loss
metabolism
body-recomposition
hgh-frag-176-191|mots-c|semaglutide|tirzepatide|adipotide
metabolic-stack|recomposition-stack
fat-loss|metabolism|body-recomposition
motsc-vs-aod9604|aod-9604-vs-semaglutide|hghfrag-vs-aod9604|adipotide-vs-aod9604
study002|study005|study026|study083|study095|study100
AOD-9604 peptide research
AOD-9604 studies|AOD-9604 fat loss|AOD-9604 vs semaglutide
AOD-9604 Research: Mechanism, Studies, and Evidence
Scientific overview of AOD-9604, including mechanism, clinical trial history, and how its evidence compares with modern obesity therapeutics.
AOD-9604 Research: Mechanism, Studies, and Evidence
Scientific overview of AOD-9604, including mechanism, clinical trial history, and how its evidence compares with modern obesity therapeutics.
What is AOD-9604?
AOD-9604 is a modified fragment of human growth hormone studied for fat-loss effects while attempting to avoid the broader anabolic and glycemic actions of full-length GH.
Does AOD-9604 work like semaglutide?
No. Semaglutide is an FDA-approved GLP-1 receptor agonist with large randomized outcome trials, जबकि AOD-9604 has a smaller and weaker evidence base centered on modest body-composition effects.
What is AOD-9604?
AOD-9604 is a modified fragment of human growth hormone studied for fat-loss effects while attempting to avoid the broader anabolic and glycemic actions of full-length GH.
AOD-9604 has more human history than many experimental peptides, but the benefit signal appears modest.
AOD-9604 has more human history than many experimental peptides, but the benefit signal appears modest|It fits educational content on body-composition science more than first-line obesity claims
Peptiders Research Team
Peptiders Clinical Review Board
MedicalWebPage
Peptide
Metabolic|Endocrine
/images/aod-9604.jpg
AOD-9604 peptide research overview
published